Penicilloyl G
Summary
Penicilloyl G, also called benzyl-penicilloyl, is the major allergenic determinant of penicillin G, formed when this antibiotic binds to lysine residues in proteins during the process of haptenisation. Benzyl penicilloyl is responsible for 90%-95% of allergic reactions associated with penicillin. Most common manifestations of allergy to the penicillin family are benign immediate and delayed cutaneous reactions, however, penicillin allergy is also the leading cause of fatal drug anaphylaxis. Clinical history alone is not reliable for the diagnosis of penicillin allergy, hence one or more among skin and blood tests for penicillin sensitization and penicillin provocation tests are required. Penicillin skin testing and penicillin-specific IgE determination are highly specific but lack diagnostic sensitivity for immediate allergic reactions. A clearly positive IgE test to penicillin has been proposed by international guidelines as a criterion for sparing drug provocation tests for penicillin allergy diagnosis.
Despite a reported global prevalence of 6%-25% for penicillin allergy, fewer than 10% of suspected cases are truly allergic to penicillin. The burden of penicillin allergy overdiagnosis has personal and public health implications. Risk factors include frequent antibiotic use, female gender, older age, a family history of allergies, and atopic conditions. Cross-reactivity between benzylpenicillins and aminopenicillins, and between penicillins and other beta-lactams, such as cephalosporins, is variable, influenced by the similarity in chemical structures.
Epidemiology
Worldwide distribution
Penicillin allergy, with an estimated prevalence of 6%-25%, is the most reported drug allergy globally. Nonetheless, <10% of people labeled as penicillin allergic have a true immunoglobulin (Ig)E-mediated hypersensitivity to penicillin, while most of these could safely tolerate penicillin. This is possibly due to two reasons: inaccurate diagnosis and the gradual diminishing of hypersensitivity with time.
In a US-based study involving 80 pediatric patients (average age 7.3 years), 73 tested positive to penicillin; 19.2% of children had hypersensitivity to penicillin G and 8.3% to benzylpenicilloyl-polylysine.
In a UK-based retrospective study on 84 adult patients (age 49.3 ± 19.4 years) with self-reported allergy to penicillins (including penicillins G and V, amoxicillin, and others), 24 (28.6%) were diagnosed with true allergy, and of them, 16 were allergic to penicillin. However, in vitro specific IgE tests of 16 penicillin-allergic patients revealed that only 3 patients (18.8%) were positive for penicilloyl G, penicilloyl V, and amoxicilloyl. A study in Slovenia aimed to assess penicillin allergy in 606 patients (average age 42 years) demonstrated that 8% (49/606) of patients had specific IgE to penicillin.
A retrospective study from the UK involving 1092 patients (age range 15-95 years) with suspected beta-lactam allergy were subjected to allergy test via skin testing performed with benzylpenicillin polylysine (PPL), minor determinants (MD) such as sodium benzylpenilloate, and also amoxicillin. About 70% of the patients tested negative for both PPL and MD. In an extensive cohort analysis of 1218 individuals with suspected beta-lactam allergies, skin test results affirmed allergies in 21.1% (n=178) of patients; of these, 84.8% (n=151) patients were positive only for penicillin.
Considerable geographical and temporal differences in terms of patient sensitization profiles to beta-lactams have been reported. In European populations, a decreased reactivity rate to PPL was observed in standard penicillin skin tests, which could be due to more prevalent amoxicillin/ampicillin allergies, especially in Southern Europe, leading to sensitization to the R-group side chain. Conversely, in the US, there is a higher tendency for hypersensitivity to the beta-lactam core of penicillin. In South Australia, a survey done in 2977 adult patients to evaluate the prevalence of self-reported drug allergy found that 9.3% of patients were allergic to penicillin. In Saudi Arabia, the prevalence of penicillin allergy was found to be approximately 9.5% in a nationwide cross-sectional survey to assess self-reported penicillin allergy prevalence in 2022 adults.
Risk factors
Frequent use of antibacterial drugs is a recognized risk factor for developing an allergy to penicillin. Drug allergy, particularly penicillin allergy, was found to be more prevalent in females and increased with age. Furthermore, the risk of penicillin allergy was increased in patients with previous negative reactions to non-beta-lactam drugs, and those with a family history of penicillin allergies, and existing atopic conditions. Patients with penicillin allergy were at an increased risk of C. difficile (26%) and methicillin-resistant S. aureus (69%) infections compared to non-penicillin allergic individuals.
Pediatric issues
In the pediatric population, approximately 5% are diagnosed with a penicillin allergy, making it a prevalent medication allergy worldwide. Upon rigorous diagnostic testing, less than 5% of these cases are validated as clinically significant immediate (IgE-dependent) or delayed (T cell-dependent) allergy to penicillin. Additionally, the differentiation between an allergic rash and a viral exanthema in children poses a differential diagnostic challenge for penicillin allergy. It was shown that about 10% of pediatric drug reaction cases are initially reported positive, but only a few are verified through detailed allergy assessments. In pediatric patients, skin tests using major and minor determinants, along with amoxicillin, without a follow-up penicillin antibiotic dose challenge, was proposed as a safe and effective method for assessing IgE-mediated penicillin hypersensitivity.
Pregnancy
The evaluation of 222 pregnant women labeled as penicillin-allergic with clinical history, appropriate skin tests and if necessary, a drug challenge test (DCT) resulted in the delabeling of 209 (95%) of these patients, confirming the overestimation of penicillin allergy diagnosis.
Route Of Exposure
Penicillin exposure occurs parenterally via intravenous or intramuscular injections of benzathine (as potassium or sodium salts).
Clinical Relevance
Penicillin allergy is acknowledged as a health challenge for hospitals and communities, with notable negative consequences on patient’s health.
Penicillin allergies are divided into two categories: immediate and delayed, each stemming from different immune responses. Immediate reactions happen within 1 to 6 hours of taking the drug, with symptom onset taking place during the first 15 minutes in 85% of patients and can range from urticaria to life-threatening anaphylaxis. Delayed reactions occur at least 6 hours after administration, with a majority taking place after 1 to 2 weeks, and may present as benign maculopapular exanthema but severe, life-threatening presentations are also reported, such as DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome, Stevens-Johnson syndrome, and toxic epidermal necrolysis (Castells et al. 2019, Khan et al. 2022,.
The majority of reports on penicillin allergy portrayed skin reactions or ‘unknown’ reactions. Penicillin allergy documentation often omits specific details, with 'unknown' reactions noted in 26% of cases in health records. Documented reactions attributed to penicillin allergy include exanthema, urticaria, angioedema, gastrointestinal symptoms, anaphylaxis, and pruritus. Among these reactions, urticaria and exanthema are the most frequently reported symptoms.
In a study involving 1348 documented penicillin-allergic adult patients, the most common allergic reactions to penicillin were exanthema (37%), urticaria (18.9%), and edema (11.8%). Anaphylaxis occurred in 6.8% of cases; however, in most of these patients (92.4%) details of anaphylactic reactions were not documented. Another study on 193 adult patients (18->65 years) with penicillin allergy reported anaphylactic reactions in 46.1% (89/193) patients and non-anaphylactic reactions in 35.8% (69/193). Exanthema (n=53) was the most commonly reported non-anaphylactic reaction, followed by pruritus (n=39) while facial edema of lips or eyes was the least reported reaction (n=6).
Similar types of allergic reactions to beta-lactam antibiotics were reported in a pediatric population. The predominant immediate reactions were non-urticarial rash (65%), followed by urticaria (32%) and angioedema (9%). Among these, 38% exhibited symptoms indicative of IgE-mediated reactions, such as urticaria, facial edema, or anaphylactic symptoms. Only one patient (1.3%) experienced a high-risk reaction involving respiratory and gastrointestinal symptoms with hemodynamic instability.
Risk stratification is vital for healthcare providers in diagnosing and managing penicillin allergies, affecting decisions regarding beta-lactam therapy or alternatives. High-risk patients may show severe immediate reactions such as anaphylaxis, low blood pressure, laryngeal edema, bronchospasm in association with urticaria, angioedema, and generalized exanthema. Conversely, low-risk patients are reported to have milder immediate reactions like isolated pruritus, gastrointestinal symptoms, contact dermatitis, or mild maculopapular exanthema.
Diagnostics
Clinical predictors for true beta-lactam allergies are lacking, hence suspected allergy cases need to be confirmed by specific IgE testing and if necessary, by an in vivo DCT.
Both skin tests and IgE tests for penicillin allergy display high specificity but insufficient sensitivity, with a systematic review and meta-analysis finding 96.8% and 97.4%, and 30.7% and 19.4%, respectively. Technical improvements in penicillin reagents for in vitro diagnosis, introduced in 2006, resulted in a reported 82% reduction of false positive penicillin-specific IgE results.
The interpretation of penicillin-specific IgE should ideally consider the level of total IgE. Low levels of penicillin-specific IgE display lower diagnostic specificity in the context of elevated total IgE levels. A study in 171 patients with immediate reactions to penicillins and positive allergy work-up found that a ratio of specific IgE to penicillins (sum of specific IgE to a panel including benzylpenicillins and aminopenicillins) to total IgE greater than 0.002 had a positive predictive value of 92.5%.
Penicillin sensitization decreases over time and may become undetectable with both skin tests and serum specific IgE. The half-life of serum specific IgE was found to be 1 year in most patients. Accordingly, penicillin allergy work-up is recommended 4-6 weeks after the drug-induced reaction and no later than one year after the index reaction. Early investigation can be performed with specific IgE determination in acute samples obtained at the time of an immediate reaction. Specific IgE testing is recommended as the first-line investigation in high-risk patients, e.g. having experienced severe immediate reactions to penicillin. A clearly positive IgE test can be considered sufficient for the diagnosis of beta-lactam allergy in patients with an evocative clinical history, especially anaphylaxis
If specific IgE tests are negative, additional examinations with skin and drug provocation test become necessary.
Conversely, USA practice parameter recommends skin testing over blood IgE testing due to lower diagnostic sensitivity of the latter.
Prevention And Therapy
Avoidance
Patients with confirmed penicillin allergy must not be administered the trigger and cross-reactive molecules, based on similar side chains, particularly those belonging to the same subclass, such as aminopenicillins. For individuals with a confirmed penicillin allergy and no available alternative treatments (such as syphilis), desensitization is necessary.
Cross-Reactivity
Different types of penicillin are reported to show partial cross-reactivity due to shared structural features such as side chains and the beta-lactam ring. Penicillin and cephalosporins share a similar beta-lactam ring and were found to have cross-reactivity in 2% of cases, which is less than the 8% reported in previous studies. However, cross-reactivity between penicillin and aminocephalosporin was found to be much higher than cephalosporin owing to the shared chemical side chains or R1 groups. Cefazolin shows very low cross-reactivity with penicillin as it contains a unique side chain. The rate of cross-reactivity between penicillin and carbapenems was <1%. Cross-reactivity between penicillins and third-generation cephalosporins affects 2% to 3% of penicillin-allergic patients.
A meta-analysis of 21 studies involving 1269 penicillin-allergic patients to determine the risk of cross-reactivity of penicillin with cephalosporins and carbapenems concluded that cross-reactivity rates between penicillin and cephalosporins/carbapenems were dependent on the similarity of R1 side chains. Cephalosporins having R-side chains similar to penicillin show more cross-reactivity than the cephalosporins with different side chains. Aminocephalosporins showed 16.5% cross-reactivity, while cephalothin, cephaloridine, and cefamandole showed 5.6% cross-reactivity and cefazolin, had a cross-reactivity rate of only 2.1%.
Explained Results
Allergen Information
Penicillin G or benzylpenicillin is a commonly prescribed beta-lactam antibiotic. Its allergenic properties require haptenization with carrier proteins such as serum albumin, followed by the generation of major and minor allergenic determinants. The major determinant (benzyl penicilloyl) is responsible for 90%-95% of allergic reactions to penicillin.
Clinical information
Penicillin hypersensitivity reactions with a demonstrated adaptive immune mechanism are termed penicillin allergy. Immediate penicillin allergy (1-6 hours after administration) is IgE-dependent while delayed penicillin allergy (>6 hours after administration) is T cell-dependent. Urticaria and exanthema are the most common symptoms. Confirmed penicillin allergy represents around 10% of patients with a label of penicillin allergy, prompting recommendations for proactive penicillin allergy delabeling worldwide.
Cross-reactivity
Different types of penicillin and cephalosporins exhibit partial cross-reactivity, mainly due to shared beta-lactam rings and similar side chains. The rate of cross-reactivity varies, being higher with aminocephalosporins due to their similar R1 side chains, while cephalosporins like cefazolin show much lower cross-reactivity due to distinct side chains.
References
- Adkinson, N. F., Jr., L. M. Mendelson, C. Ressler and J. C. Keogh (2018). "Penicillin minor determinants: History and relevance for current diagnosis." Ann Allergy Asthma Immunol 121(5): 537-544.
- Albin, S. and S. Agarwal (2014). "Prevalence and characteristics of reported penicillin allergy in an urban outpatient adult population." Allergy Asthma Proc 35(6): 489-494.
- Alowais, S. A., S. N. Almohareb, K. Bin Saleh, I. M. Asiri, H. A. Badreldin, L. Alqazlan, M. Albasseet, L. Fetyani, L. A. Alshehri and A. M. Almutairi (2023). "Assessing the prevalence and characteristics of self-reported penicillin allergy in Saudi Arabian population: A nationwide cross-sectional study." Saudi Pharm J 31(2): 222-227.
- Anterasian, C. M. and B. Geng (2018). "Penicillin skin testing in the management of penicillin allergy in an outpatient pediatric population." Allergy Asthma Proc 39(4): 305-310.
- Apter A.J., H. Schelleman, A. Walker, K. Addya and T. Rebbeck (2008). "Clinical and genetic risk factors of self-reported penicillin allergy." J Allergy Clin Immunol 122(1):152-8.
- Bhattacharya, S. (2010). "The Facts About Penicillin Allergy: A Review." Journal of Advanced Pharmaceutical Technology & Research 1(1):11-17.
- Bousquet, P. J., A. Pipet, L. Bousquet-Rouanet and P. Demoly (2008). "Oral challenges are needed in the diagnosis of beta-lactam hypersensitivity." Clin Exp Allergy 38(1): 185-190.
- Brockow, K., W. Pfützner, B. Wedi, G. Wurpts, A. Trautmann, B. Kreft, T. Buhl, M. Sulk, A. Recke, K. Scherer, S. Wöhrl, I. Neustädter, R. Treudler, C. Querbach and M. Worm (2025). “Recommendations on how to proceed in case of suspected allergy to penicillin/β-lactam antibiotics: Position paper of the German Society for Allergology and Clinical Immunology (DGAKI) in cooperation with the German Society for Pediatric Allergology (GPA), Austrian Society for Allergology and Immunology (ÖGAI) and the Swiss Society for Allergology and Immunology (SGAI)”. Allergol Select 6(9):28-39.
- Castells, M., D. A. Khan and E. J. Phillips (2019). "Penicillin Allergy." N Engl J Med 381(24): 2338-2351.
- CDC. (2022). "Managing Persons Who Have a History of Penicillin Allergy." Retrieved 4 December 2023, from https://www.cdc.gov/std/treatment-guidelines/penicillin-allergy.htm.
- D'Errico, S., P. Frati, M. Zanon, E. Valentinuz, F. Manetti, M. Scopetti, A. Santurro and V. Fineschi (2020). "Cephalosporins' Cross-Reactivity and the High Degree of Required Knowledge. Case Report and Review of the Literature." Antibiotics (Basel) 9(5): 209.
- Demoly, P., N. F. Adkinson, K. Brockow, M. Castells, A. M. Chiriac, P. A. Greenberger, D. A. Khan, D. M. Lang, H. S. Park, W. Pichler, M. Sanchez-Borges, T. Shiohara and B. Y. Thong (2014). "International Consensus on drug allergy." Allergy 69(4): 420-437.
- D‘Netto, M.,Voelker, D. and M. Park (2022). "Pediatric penicillin skin testing with minor determinants and amoxicillin with or without oral drug challenge." Ann Allergy Asthma Immunol 128(5): 609-610.
- Dona, I., M. Salas, E. Moreno, M. Ferrer, C. Mayorga and M. J. Torres (2025). "An algorithm for the diagnosis of beta-lactam allergy, 2024 update." Allergy 80(2): 633-637.
- Garvey, L. H., D. G. Ebo, P. M. Mertes, P. Dewachter, T. Garcez, P. Kopac, J. J. Laguna, A. M. Chiriac, I. Terreehorst, S. Voltolini and K. Scherer (2019). "An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactions." Allergy 74(10): 1872-1884.
- Hjortlund, J., C. G. Mortz, T. B. Stage, P. S. Skov, R. Dahl and C. Bindslev-Jensen (2014). "Positive serum specific IgE has a short half-life in patients with penicillin allergy and reversal does not always indicate tolerance." Clin Transl Allergy 4: 34.
- Kado, J. H., S. Salman, R. Henderson, R. Hand, R. Wyber, M. Page-Sharp, K. Batty, J. Carapetis and L. Manning (2020). "Subcutaneous administration of benzathine benzylpenicillin G has favourable pharmacokinetic characteristics for the prevention of rheumatic heart disease compared with intramuscular injection: a randomized, crossover, population pharmacokinetic study in healthy adult volunteers." J Antimicrob Chemother 75(10): 2951-2959.
- Khan, D. A., A. Banerji, K. G. Blumenthal, E. J. Phillips, R. Solensky, A. A. White, J. A. Bernstein, D. K. Chu, A. K. Ellis, D. B. K. Golden, M. J. Greenhawt, C. C. Horner, D. Ledford, J. A. Lieberman, J. Oppenheimer, M. A. Rank, M. S. Shaker, D. R. Stukus, D. Wallace, J. Wang, E. Chief, D. A. Khan, D. B. K. Golden, M. Shaker, D. R. Stukus, C. Workgroup, D. A. Khan, A. Banerji, K. G. Blumenthal, E. J. Phillips, R. Solensky, A. A. White, R. Joint Task Force on Practice Parameters, J. A. Bernstein, D. K. Chu, A. K. Ellis, D. B. K. Golden, M. J. Greenhawt, C. C. Horner, D. Ledford, J. A. Lieberman, J. Oppenheimer, M. A. Rank, M. S. Shaker, D. R. Stukus, D. Wallace and J. Wang (2022). "Drug allergy: A 2022 practice parameter update." J Allergy Clin Immunol 150(6): 1333-1393.
- Kopač P., M. Zidarn and M. Kosnik (2012). "Epidemiology of hypersensitivity reactions to penicillin in Slovenia." Acta Dermatovenerologica 21(4): 65-67.
- Kouma, M. A., J. M. Guastadisegni, L. Yang, D. N. Maxwell, D. F. Storey and R. J. Arasaratnam (2023). "Challenges and opportunities related to penicillin allergy in the Veterans Health Administration: a narrative review." Antimicrob Steward Healthc Epidemiol 3(1): e174.
- Kwok, M., K. L. Heard, A. May, R. Pilgrim, J. Sandoe, S. Tansley and J. Scott (2023). "Health outcomes of penicillin allergy testing in children: a systematic review." J Antimicrob Chemother 78(4): 913-922.
- Lendal, V., S. Fransson, H. Mosbech, J. B. Boel, N. Kahlhofen, L. H. Blom, L. K. Poulsen and L. H. Garvey (2023). "Specific IgE to penicillin minor determinants in patients with suspected penicillin allergy." Clin Exp Allergy 53(8): 887-890.
- Lendal, V., S. Fransson, H. Mosbech, J. B. Boel, N. Kahlhofen, L. H. Blom, L. K. Poulsen and L. H. Garvey (2025). "Clinical Relevance of Specific IgE in Penicillin Allergy Investigation." Int Arch Allergy Immunol. 186(4):303-310.
- Lobanovska, M. and G. Pilla (2017). "Penicillin’s Discovery and Antibiotic Resistance: Lessons for the Future?" Yale J Biol Med 90(1): 135-145.
- Lteif, L. and L. S. Eiland (2019). "The Basics of Penicillin Allergy: What A Clinician Should Know." Pharmacy (Basel) 7(3):94.
- Macy, E. and K. G. Blumenthal (2018). "Are Cephalosporins Safe for Use in Penicillin Allergy without Prior Allergy Evaluation?" J Allergy Clin Immunol Pract 6(1): 82-89.
- Meng, J., D. Thursfield and J. J. Lukawska (2016). "Allergy test outcomes in patients self-reported as having penicillin allergy: Two-year experience." Ann Allergy Asthma Immunol 117(3): 273-279.
- Picard, M., G. Robitaille, F. Karam, J. M. Daigle, F. Bedard, E. Biron, M. R. Tardif, J. Lacombe-Barrios and P. Begin (2019). "Cross-Reactivity to Cephalosporins and Carbapenems in Penicillin-Allergic Patients: Two Systematic Reviews and Meta-Analyses." J Allergy Clin Immunol Pract 7(8): 2722-2738.e5.
- Piccorossi, A., G. Liccioli, S. Barni, L. Sarti, M. Giovannini, A. Verrotti, E. Novembre and F. Mori (2020). "Epidemiology and drug allergy results in children investigated in allergy unit of a tertiary-care paediatric hospital setting." Ital J Pediatr 46(1): 5.
- Romano, A., M. Atanaskovic-Markovic, A. Barbaud, A. J. Bircher, K. Brockow, J. C. Caubet, G. Celik, J. Cernadas, A. M. Chiriac, P. Demoly, L. H. Garvey, C. Mayorga, A. Nakonechna, P. Whitaker and M. J. Torres (2020). "Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper." Allergy 75(6): 1300-1315.
- Sacco, K. A., A. Bates, T. J. Brigham, J. S. Imam and M. C. Burton (2017). "Clinical outcomes following inpatient penicillin allergy testing: A systematic review and meta-analysis." Allergy 72(9): 1288-1296.
- Shenoy, E. S., E. Macy, T. Rowe and K. G. Blumenthal (2019). "Evaluation and Management of Penicillin Allergy: A Review." JAMA 321(2): 188-199.
- Siew, L. Q. C., P. H. Li, T. J. Watts, I. Thomas, K. L. Ue, M. R. Caballero, K. Rutkowski, S. J. Till, P. Pillai and R. Haque (2019). "Identifying Low-Risk Beta-Lactam Allergy Patients in a UK Tertiary Centre." J Allergy Clin Immunol Pract 7(7): 2173-2181.e1.
- Sousa-Pinto, B., I. Tarrio, K. G. Blumenthal, L. Araujo, L. F. Azevedo, L. Delgado and J. A. Fonseca (2021). "Accuracy of penicillin allergy diagnostic tests: A systematic review and meta-analysis." J Allergy Clin Immunol 147(1): 296-308.
- Trubiano, J. A., S. Vogrin, K. Y. L. Chua, J. Bourke, J. Yun, A. Douglas, C. A. Stone, R. Yu, L. Groenendijk, N. E. Holmes and E. J. Phillips (2020). "Development and Validation of a Penicillin Allergy Clinical Decision Rule." JAMA Intern Med 180(5): 745-752.
- Vivo, A., M. J. Durkin, I. Kale, T. Boyer, M. A. Fitzpatrick, C. T. Evans, M. M. Jurasic, G. Gibson and K. J. Suda (2022). "Opportunities for penicillin allergy evaluation in dental clinics." Antimicrob Steward Healthc Epidemiol 2(1): e58.
- Vultaggio, A., A. Matucci, G. Virgili, O. Rossi, L. Fili, P. Parronchi, S. Romagnani and E. Maggi (2009). "Influence of total serum IgE levels on the in vitro detection of beta-lactams-specific IgE antibodies." Clin Exp Allergy 39(6): 838-844.
- Vultaggio, A., G. Virgili, F. Gaeta, A. Romano, E. Maggi and A. Matucci (2015). "High serum beta-lactams specific/total IgE ratio is associated with immediate reactions to beta-lactams antibiotics." PLoS One 10(4): e0121857.
- Wolfson, A. R., C. M. Mancini, A. Banerji, X. Fu, A. S. Bryant, N. A. Phadke, E. S. Shenoy, W. Arman, Y. Zhang and K. G. Blumenthal (2021). "Penicillin Allergy Assessment in Pregnancy: Safety and Impact on Antibiotic Use." J Allergy Clin Immunol Pract 9(3): 1338-1346.
- Wright, A. J. (1999). "The penicillins." Mayo Clin Proc 74(3): 290-307.
- Yuson, C., S. Shakib and W. Smith (2022). "Prevalence of drug allergy in South Australia." Intern Med J 52(11): 1957–1961.
- Zidarn, M., M. Silar, M. Vegnuti, P. Korosec and M. Kosnik (2009). "The specificity of tests for anti-beta-lactam IgE antibodies declines progressively with increase of total serum IgE." Wien Klin Wochenschr 121(9-10): 353-356.